Total amount: € 0,00
HOW TO ORDER
A Journal on Angiology
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
International Angiology 2006 March;25(1):60-6
Recurrent venous thromboembolism in patients with and without anticoagulation after inferior vena caval filter placement
Yale S. H. 1,2, Mazza J. J. 2,3, Glurich I. 2, Peters T. 2, Mukesh B. N. 4
1 Department of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA
2 Clinical Research Center, Marshfield Clinic Research Foundation, Marshfield, WI, USA
3 Department of Hematology/Oncology, Marshfield Clinic, Marshfield, WI, USA
4 Biostatistics and Bioinformatics Core, Marshfield Clinic Research Foundation Marshfield, WI, USA
Aim. The aim of this study was to compare the rate of recurrent venothromboembolic (VTE) events and factors contributing to VTE events in patients with inferior vena caval (IVC) filters on chronic anticoagulation to those in whom anticoagulation was discontinued.
Methods. Retrospective cohort study of 353 patients who received IVC filters between 1986 and 2002.
Results. Anticoagulation status was available for 304 patients (132 on coumadin anticoagulation therapy and 172 who did not receive any anticoagulation therapy) whose IVC filters were placed within 30 days of their qualifying thromboembolic event. Two-year event-free survival for the anticoagulated group was 80.6% (95% confidence interval—CI—76.9, 84.3] and was 67.8% (95% CI 63.2, 72.3) for the non-anticoagulated group. Patients who had Greenfield filter had a higher, but not statistically significant different, rate of recurrence compared to those with other types of filters (hazard ratio 1.4; 95% CI 0.9, 2). The rate of recurrent VTE events was independent of age, gender, smoking status, or underlying medical condition.
Conclusion. Among those with IVC filters, long-term anticoagulation therapy prolonged event-free survival for up to 2 years but did not prevent recurrent VTE events.